Back

The drug and the PARADIGM-HF trial.

22 May 2016 (16:30 - 16:42)
Organised by:
Congress Presentation Part of: What a busy clinician needs to know about LCZ696 for heart failure Miscellaneous HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
What was it approved for in Europe – The EMA recommendations.
Doctor K. Prasad (London, GB)
Slides Video
Presentation thumbnail
What the 2016 guidelines say.
Professor P. Ponikowski (Wroclaw, PL)
Slides Video
Presentation thumbnail
LCZ696 and the use of biomarkers.
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
LCZ696 and Alzheimers?
Professor A. Zeiher (Frankfurt, DE)
Slides Video
Presentation thumbnail
LCZ696 and drug-drug interactions?
Professor G. Rosano (London, GB)

Access the full session

Session thumbnail
What a busy clinician needs to know about LCZ696 for heart failure

The Event

Event poster

HEART FAILURE 2016

22 May 2016 16:30 CET
You may be interested in
thumbnail
Congress Session
Is left ventricular ejection fraction still relevant for guideline-directed medical therapy implementation?
18 May 2025
thumbnail
Congress Presentation
Safety and tolerability of sacubitril/valsartan in chronic heart failure and reduced ejection fraction: results from the open-label extension of PARADIGM-HF
21 May 2023
thumbnail
Congress Session
Hottest trials and trial updates (2)
18 May 2025
thumbnail
Congress Presentation
Discussant review - PARADISE-MI .
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources